Search

Your search keyword '"Ji, Qinghua"' showing total 12 results
Start Over Author "Ji, Qinghua" Publisher wiley
12 results on '"Ji, Qinghua"'

12. Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma.

Author

Ji Q, Cai Y, Shrestha SM, Shen D, Zhao W, and Shi R

Subjects
BRCA2 Protein genetics, Biomarkers, Pharmacological, Carrier Proteins genetics, Claudin-1 genetics, Computational Biology methods, Databases, Genetic, Esophageal Neoplasms genetics, Esophageal Neoplasms immunology, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma pathology, Gene Expression genetics, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic genetics, Gene Regulatory Networks genetics, Humans, Prognosis, Receptors, G-Protein-Coupled genetics, Receptors, Nicotinic genetics, Transcriptome genetics, Esophageal Squamous Cell Carcinoma genetics, Esophageal Squamous Cell Carcinoma immunology
Abstract

Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC dataset were selected using the weighted gene coexpression network and lasso Cox regression analyses. Based on these data, an immune-related gene prognostic index (IRGPI) was constructed. The molecular characteristics of the different IRGPI subgroups were assessed using mutation information and gene set enrichment analysis. Differences in immune cell infiltration and the response to ICI therapy and other drugs were also analyzed. Additionally, tumor and adjacent control tissues were collected from six patients with ESCC and the expression of these genes was verified using real-time quantitative polymerase chain reaction. IRGPI was designed based on CLDN1 , HCAR3 , FNBP1L , and BRCA2 , the expression of which was confirmed in ESCC samples. The prognosis of patients in the high-IRGPI group was poor, as verified using publicly available expression data. KMT2D mutations were more common in the high-IRGPI group. Enrichment analysis revealed an active immune response, and immune infiltration assessment showed that the high-IRGPI group had an increased infiltration degree of CD8 T cells, which contributed to the improved response to ICI treatment. Collectively, these data demonstrate that IRGPI is a robust biomarker for predicting the prognosis and response to therapy of patients with ESCC., Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper., (Copyright © 2021 Qinghua Ji et al.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results